First-line combination immunotherapy for metastatic non-small cell lung cancer.

J Chin Med Assoc · 2020 · PMC13048123 · PMID 32132380

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, indirect retrospective review of data from different clinical trials of the first-line single anti-PD1 treatment and anti-PD(L)1 + chemotherapy treatment studies showed a trend of better response rate and PFS (Tables 2 – 4 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.